NASDAQ · STOK
Healthcare · Biotechnology
$28.15
Up+$0.01 (+0.02%)
Updated Sep 16, 2026, 5:12 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
STOK closed at $28.15 after 20 trading sessions, down 12.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $29.56 | $29.56 | $27.82 | $28.15 | 1.09M |
| Sep 14, 2026 | $29.38 | $29.70 | $29.01 | $29.60 | 500.37K |
| Sep 11, 2026 | $29.82 | $30.16 | $29.01 | $29.03 | 587.52K |
| Sep 10, 2026 | $29.62 | $29.785 | $28.96 | $29.34 | 421.3K |
| Sep 9, 2026 | $29.53 | $30.53 | $29.53 | $29.92 | 666.27K |
| Sep 8, 2026 | $29.13 | $30.68 | $28.885 | $30.05 | 680.96K |
| Sep 4, 2026 | $29.41 | $30.0275 | $29.145 | $29.81 | 714.06K |
| Sep 3, 2026 | $30.70 | $30.70 | $29.69 | $29.99 | 512.26K |
| Sep 2, 2026 | $31.46 | $32.12 | $29.98 | $30.50 | 631.32K |
| Sep 1, 2026 | $29.94 | $31.38 | $29.94 | $30.89 | 727.5K |
| Aug 31, 2026 | $31.37 | $32.175 | $30.58 | $31.20 | 1.12M |
| Aug 28, 2026 | $32.20 | $32.55 | $31.49 | $31.62 | 754.1K |
| Aug 27, 2026 | $33.01 | $33.18 | $32.0005 | $32.59 | 939.34K |
| Aug 26, 2026 | $33.21 | $33.55 | $32.57 | $33.09 | 1.16M |
| Aug 25, 2026 | $32.70 | $33.94 | $32.45 | $33.46 | 728.63K |
| Aug 24, 2026 | $32.29 | $32.76 | $31.16 | $32.32 | 562.29K |
| Aug 21, 2026 | $31.76 | $32.765 | $31.52 | $32.29 | 1.27M |
| Aug 20, 2026 | $32.48 | $32.59 | $29.86 | $31.40 | 1.49M |
| Aug 19, 2026 | $32.75 | $33.43 | $32.52 | $33.03 | 1.47M |
| Aug 18, 2026 | $31.85 | $32.67 | $31.40 | $32.14 | 574.55K |
The latest Smart Investors Daily articles mentioning STOK.
STOK research
Company profile and research snapshot.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Overweight | — |
| Aug 4, 2026 | Guggenheim | Buy | — |
| Aug 4, 2026 | Wedbush | Outperform | — |
| Aug 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 4, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 4, 2026
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
Yahoo · Sep 3, 2026
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zore
Yahoo · Sep 2, 2026
BEDFORD, Mass., September 02, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare
Yahoo · Sep 1, 2026
BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STOK.
